We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.36 | -0.28% | 128.44 | 129.76 | 127.985 | 129.76 | 7,441,700 | 22:02:26 |
From May 2019 to May 2024
By Michael Dabaie
Myriad Genetics Inc. (MYGN) said it submitted a supplementary premarket approval application to the U.S. Food and Drug Administration.
The sPMA is for the company's BRACAnalysis CDx test as a companion diagnostic to AstraZeneca PLC's (AZN) and Merck & Co.'s (MRK) Lynparza for men with metastatic castration-resistant prostate cancer.
AstraZeneca and Merck said Tuesday the supplemental New Drug Application for Lynparza was been accepted and granted priority review by the FDA.
Myriad said the filing for BRACAnalysis CDx is based on the positive clinical results from the PROfound study.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 21, 2020 07:43 ET (12:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
